During the past trading week (June 10 to 14), the Canadian government announced the edibles and infused marketplace will be available by the end of 2019.

A new plan from a marijuana producer to lock up a majority of its shares made headlines, while the expansion of a credit card program from a US-based marijuana operator also caught attention.

Here’s a closer look at some of the biggest news during last week’s trading period.

Edibles in Canada coming in mid-December

As part of the legalization of cannabis, Canada unveiled its final set of regulations for the introduction of edible and infused products. On Friday (June 14), the government confirmed the regulations will come into force on October 17, a year after the first round of legalization in Canada.

“As required by the Cannabis Act, the amended regulations will come into force on October 17, 2019. However, it will take time, after that date, before new cannabis products become available for purchase,” Health Canada said in a release.

According to the government, the earliest these products will be sold is December 16, 2019. The launch will see a limited selection of products that will appear “gradually” in both physical retail and online portals, said the government.

“Additionally, as with any new regulatory framework, federally licensed processors will need time to become familiar with and prepare to comply with the new rules, and to produce new products,” the government said. “Provincially or territorially authorized distributors and retailers will also need time to purchase and obtain the new products and make them available for sale.”

The government confirmed the full regulations will be published and shared with the public on June 26, 2019. Edible products will face a limit of 10 milligrams of tetrahydrocannabinol (THC) per package.

Similar to the first round of legalization, all of these new products will face heavy restrictions on packaging and promotion.

In a recent report projecting the value of the upcoming Canadian edibles and infused market, Deloitte indicated the start of this market will be tumultuous to consumers.

“There will be missteps, delays, and frustration,” Deloitte states in the document. The projection from the research gives a value of C$2.7 billion per year to the total edibles and infused space, with edibles accounting for C$1.6 billion.

“According to our research and stakeholder interviews, much of this economic boost will be on top of current cannabis product spending,” Jennifer Lee, partner at Deloitte and the firm’s cannabis leader for Canada, said in a press release.

An unreleased consumer study from Lift & Co. (TSXV:LIFT,OTCQB:LFCOF) and EY indicates the edibles market will attract 1.5 million new consumers to the market.

One of the presenters of the new study, Ashley Chiu, EY’s cannabis strategic growth and risk leader, told the Investing News Network that a wide margin of consumers will be entering the edibles market without a lot of information on the products and the effects of these.

Because of this lack of information, budtenders will play a crucial role in the education of consumers, according to Chiu.

MSO expands credit card program in the US

On Thursday (June 13), New York-based multi-state operator (MSO) Columbia Care (NEO:CCHW) announced it will broaden the reach of its exclusive Columbia National Credit program (CNC Card) in the US.

Under this program, consumers can apply for a unique credit card that works for cannabis purchases in dispensaries owned by the MSO. After an initial test run in New York, the firm aims to have the program ready in Delaware, Pennsylvania, Illinois and Arizona by the end of June.

“Based on our success in New York … we are confident that the CNC Card has the potential to be a significant value add for the company and for all of our customers who look to us for reliable and convenient high-quality health and wellness options,” Nicholas Vita, CEO of Columbia Care, said in a press release.

The firm indicated that, since introducing the card in New York, the “average basket size for in-store purchases” has gone up by 18 percent.

Tilray secures shareholder lock-up

In an attempt to combat speculation on its stock performance, Tilray (NASDAQ:TLRY) announced an intricate agreement with its leading shareholder Privateer Holdings.

According to a new arrangement between the two firms, Tilray will acquire Privateer in what is referred to as a downstream merger. After the acquisition is completed, Tilray will issue Privateer shareholders a new set of the marijuana firm’s shares. These new shares will be placed on lockup for a two year period.

Tilray indicated the new agreement with Privateer will extend the current lockup of 75 million shares of the marijuana company. Privateer owns approximately 77 percent of Tilray’s total outstanding shares.

“We believe this transaction will give Tilray greater control and operating flexibility, while allowing us to effectively manage our public float,” Mark Castaneda, chief financial officer of Tilray, said in a press release.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.


US Election 2020 and Cannabis

 
Investing in cannabis? Read what experts have to say about cannabis and the US Election!
 

  • Company surpassed 5,600 patient prescriptions for its medical cannabis products in Colombia . Prescriptions filled increased over 450% in Q3 2020 over Q2 2020
  • Khiron declared a National Strategic Project by the Government of Colombia , simplifying and accelerating administration and processes for the Company in executing strategic projects in Colombia and for export
  • Subsequent to the quarter, the Company completed a bought deal financing on November 26, 2020 , selling 32,200,000 units at a price of $0.45 per unit for aggregate gross proceeds of $14,490,000 CAD
  • Khiron signed partnerships with 15 clinics and health centres in Colombia , extending education and sales reach further across the country
  • As a result of the Company’s Doctor Zerenia TM telehealth platform more than 25% of the Company’s medical cannabis prescriptions came from outside of Bogota , expanding geographic presence of its Colombian clinics
  • Company achieved first sales of High CBD medical cannabis through private pharmacies in Peru . Additional approval received from Peru’s drug regulatory authority for Company’s High THC cannabis, with first prescriptions anticipated in Q1 2021
  • Expanded medical cannabis E-Learning platform to UK market in partnership with Medical Cannabis Clinicians Society (“MCCS”)
  • Entered an exclusive partnership with Rappi SAS, Latin America’s largest home multi-vertical app platform to distribute the Company’s CPG product portfolio, introducing Kuida products to Rappi users across the LatAm region
  • Signed agreement to distribute the Company’s Kuida TM CBD skincare brand through pharmacy, beauty retail and online markets serving the Hong Kong territory, with first orders expected in Q4 2020
  • Prudent cash use of $5 million in Q3 2020, compared with $4 million in Q2 2020, $12 million in Q1 2020 and $10 million in Q4 2019

 Khiron Life Sciences Corp. (“Khiron” or the “Company”) (TSXV: KHRN ), (OTCQX: KHRNF), ( Frankfurt : A2JMZC), a vertically integrated cannabis leader with core operations in Latin America and Europe announced today its financial results for the quarter ended September 30, 2020 . These filings are available for review on the Company’s SEDAR profile at www.sedar.com All financial information in this press release is reported in Canadian dollars, unless otherwise indicated.

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less
  • Q3 Systemwide Pro Forma Revenue increased 18% quarter-over-quarter to $22.3 million , 170% year-over-year – Company became cash flow positive from operations in August
  • Company sale leaseback transaction with Innovative Industrial Properties scheduled to close within two weeks. As a result of close, together with proceeds from the recently closed bought deal financing, the Company will have $16 million of cash and $43 million in long-term debt
  • Company is in the process of acquiring acreage to construct up to 210,000 square feet of flowering canopy and supporting manufacturing facility in Cook County, Illinois to exponentially increase capacity in state
  • Initial guidance for 2021 with Systemwide Pro Forma Revenue of $170 -180 million and Adjusted EBITDA of $40 -50 million
  • The Company’s existing projects at maturity represent a long-term revenue and EBITDA opportunity upwards of $650 million and $250 million

4Front Ventures Corp. (CSE: FFNT) (OTCQX: FFNTF) (” 4Front ” or the ” Company “) today announced its financial results for the third quarter of 2020. All financial information is presented in U.S. dollars unless otherwise indicated.

Third Quarter 2020 Financial Results Highlights

Keep reading... Show less

Shareholders with losses exceeding $50,000 are encouraged to contact the firm

The Law Offices of Frank R. Cruz reminds investors of the upcoming December 1, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased Aurora Cannabis, Inc. (“Aurora” or the “Company”) (NYSE: ACB ) securities between February 13, 2020 and September 4, 2020 , inclusive (the “Class Period”).

Keep reading... Show less

Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) is pleased to announce the launch of preclinical research studies using psilocybin and N-Acetylcysteine (“NAC”) for the treatment of mild traumatic brain injuryconcussion (“mTBI”) with post-traumatic stress disorder (“PTSD”). The study is in collaboration with a multidisciplinary team of scientists and physicians at the University of Miami Miller School of Medicine under the lead of Michael E. Hoffer, M.D., professor of otolaryngology and neurological surgery.

NAC has been shown to be safe and efficacious in a phase I human clinical study in treating military personnel who had suffered mTBI. The initial research focus is to demonstrate the safety and efficacy of the combination of psilocybin and NAC using broadly accepted rodent models. Final results are expected in 2021. Once this is established, more specific work can examine dose response, medicine uptake, and medicine levels. The research team at the Miller School of Medicine has conducted prior studies involving NAC with mTBI and has a license from the United States Drug Enforcement Administration to conduct research using Schedule I controlled substances, which includes psilocybin.

Keep reading... Show less